Over the past few years, InSite Vision has been investigating drug formulations that utilize DuraSite®, our drug delivery system. DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules, like the antibiotic azithromycin, in an aqueous matrix. Safety studies have shown DuraSite drug delivery to be non-toxic and biocompatiblele.*
In addition to these properties, DuraSite can be customized to deliver a wide variety of potential drug candidates. The loading capacity of DuraSite ensures therapeutic doses, and the DuraSite matrix is capable of residing on the ocular surface 4-6 hours, during which time the active drug is gradually released.
The increased time that DuraSite remains in the eye allows lower concentrations of a drug to be administered over a longer period of time. This provides more convenient dosing, reduces the potential of adverse side effects, and may lead to improved patient compliance.
*Final Assessment Report of the Safety of Carbomers -934, -934P, -940, -941, and –962. J Amer College Toxicol . 1982;1(2):109-141. Br. J. Ophthalmol 2003, 87:436-440.